Randomized double-blind placebo-controlled prospective, parallel, multicentre clinical trial of bacterial polivalent vaccine (BACTEK) administered by sublingual mucosa in subjects with chronic obstructive pulmonary disease (COPD) for efficacy evaluation, security and immunomodulatory response.

Trial Profile

Randomized double-blind placebo-controlled prospective, parallel, multicentre clinical trial of bacterial polivalent vaccine (BACTEK) administered by sublingual mucosa in subjects with chronic obstructive pulmonary disease (COPD) for efficacy evaluation, security and immunomodulatory response.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs MV 130 (Primary)
  • Indications Bacterial infections; Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Inmunotek
  • Most Recent Events

    • 02 Mar 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2019.
    • 02 Mar 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2019.
    • 12 Jun 2015 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top